The Implications of the SPARTAN Trial in the treatment of nmCRPC in Clinical Practice - Conversation with Eric Small

April 28, 2018

(Length of Discussion: 23 min)

Eric Small discusses (SPARTAN), the Study of Apalutamide in Men With Non-Metastatic Castration-Resistant Prostate Cancer with Alicia Morgans.  He reviews the trial and the practical clinical practice questions that the data raises.  He details the logic behind the development of the study and the unmet need for this patient population. Other key points discussed include the “Daring” second PFS endpoint, no shortage of M0 patient population, the FDA approval of apalutamide for treatment of this patient population on the metastases-free survival (MFS) endpoint along with imaging strategies that should be considered in clinical practice.

Eric J. Small, MD Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF Deputy Director; Program Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF

Alicia Morgans, MD, MPH

Further Related Content:

Watch: First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small

First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer